Syndax Pharmaceuticals (STU:1T3) Cash from Discontinued Operating Activities : €0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Syndax Pharmaceuticals's Cash from Discontinued Operating Activities for the three months ended in Mar. 2025 was €0.00 Mil. It means Syndax Pharmaceuticals received €0.00 Mil from discontinued investing activities. Syndax Pharmaceuticals's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

Syndax Pharmaceuticals Cash from Discontinued Operating Activities Historical Data

The historical data trend for Syndax Pharmaceuticals's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Cash from Discontinued Operating Activities Chart

Syndax Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash from Discontinued Operating Activities

Get a 7-Day Free Trial

Syndax Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash from Discontinued Operating Activities	Get a 7-Day Free Trial															-	-	-	-	-

Syndax Pharmaceuticals Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Syndax Pharmaceuticals Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Cash from Discontinued Operating Activities

Comparable Companies

Traded in Other Exchanges

SNDX:USA

Address

730 Third Avenue, 9th Floor, New York, NY, USA, 10017

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals Headlines

No Headlines